ENTERO · NSE
Entero Healthcare Solutions Limited
₹1,732.3
+3.94% (+₹65.7)
Prev. close
₹1,666.6
Volume
2,44,661
Delivery %
46.9%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Entero Healthcare Solutions Limited
Entero Healthcare Solutions Limited engages in the trading of pharmaceutical and surgical products in India. The company offers a range of pharmaceuticals and other healthcare products to retail pharmacies and healthcare practitioners; and healthcare products, including pharmaceutical and nutraceutical products and vaccines; medical devices, such as orthopaedic implants and coronary stents; and hospital consumables comprising examination and surgical gloves, syringes, needles, and sutures to hospitals and clinics. It also provides private label products under the Entero Surgicals private label, such as monitoring devices, nursing and rehabilitation products, and consumables; commercial solutions; and healthcare product distribution solutions, including imports, central warehousing, redistribution, last mile delivery, and connection with the pharmacies, hospitals, and clinics. The company was incorporated in 2018 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Medical Distribution
CEO
Mr. Prabhat Agrawal
Headquarters
Mumbai
Employees
4,671
Website
enterohealthcare.comExchange
View on NSE ↗Key stats
Market cap
₹7,539.50 Cr
P/E ratio (TTM)
60.1
EPS (TTM)
₹28.83
Beta (1Y · daily vs NIFTY 50)
0.32
Shares float
1.59 Cr
EPS · quarter ended Jun 2026
₹8.76
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Debt/equity omitted where reported equity was zero or negative. Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹3,293.14 Cr | ₹3,922.31 Cr | ₹5,095.78 Cr | ₹6,591.21 Cr | |
| EBITDA | — | — | ₹64.95 Cr | ₹121.05 Cr | ₹206.97 Cr | ₹271.67 Cr |
| ₹-16.00 Cr | ₹-30.00 Cr | ₹-11.56 Cr | ₹39.11 Cr | ₹94.82 Cr | ₹115.04 Cr | |
| Diluted EPS | — | — | ₹-2.66 | ₹10.81 | ₹21.76 | ₹26.4 |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹836.00 Cr | ₹1,125.00 Cr | ₹1,308.00 Cr | ₹2,345.00 Cr | ₹2,703.00 Cr | ₹3,600.00 Cr | |
| — | — | ₹437.76 Cr | ₹337.97 Cr | ₹385.23 Cr | ₹677.15 Cr | |
| Stockholders' equity | ₹31.90 Cr | ₹58.00 Cr | ₹-69.00 Cr | ₹1,638.00 Cr | ₹1,725.00 Cr | ₹1,689.00 Cr |
Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹-69.00 Cr | ₹-35.00 Cr | ₹-45.00 Cr | ₹-37.00 Cr | ₹-77.00 Cr | ₹96.00 Cr | |
| Investing cash flow | — | — | ₹-48.60 Cr | ₹-705.12 Cr | ₹219.80 Cr | ₹-303.06 Cr |
| ₹89.00 Cr | ₹211.00 Cr | ₹73.00 Cr | ₹863.00 Cr | ₹-74.00 Cr | ₹124.00 Cr | |
| Capital expenditure | — | — | ₹-5.52 Cr | ₹-5.42 Cr | ₹-11.31 Cr | ₹-67.54 Cr |
| End cash position | — | — | ₹25.36 Cr | ₹147.65 Cr | ₹229.28 Cr | ₹146.88 Cr |
Investing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Feb 24–Dec 24(5Q) | Mar 25–Mar 26(5Q) | Jun 26 |
|---|---|---|---|
| Promoter | 52.44% | 52.42% | 52.40% |
| Public | 47.56% | 47.58% | 47.60% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Entero Healthcare Solutions Limited | ₹7,882.03 Cr | ₹1,815.4 | 62.8 | 4.67 | 6.8% | 0.40 | +29.1% | +55.3% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Show all 11
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
3 indices
Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.